TABLE 8.

Susceptibilities of C. krusei, C. inconspicua, and C. norvegensis to fluconazole and voriconazole by clinical servicea

Clinical service (total no. of isolates)Antifungal agentC. kruseiC. inconspicuaC. norvegensis
No. of isolates tested% RbNo. of isolates tested% RNo. of isolates tested% R
Hematology-oncology (11,930)Fluconazole75783.111351.32450.0
Voriconazole7419.61135.3244.2
Medical (47,024)Fluconazole1,12879.910142.66833.8
Voriconazole1,1067.81014.0682.9
Surgical (12,659)Fluconazole31678.56261.32528.0
Voriconazole3205.6621.6250.0
ICU (27,758)Fluconazole70679.07850.02642.3
Voriconazole6926.6762.6260.0
Dermatology (3,001)Fluconazole3271.9475.020.0
Voriconazole316.5450.020.0
Urology (1,954)Fluconazole4060.0425.0683.3
Voriconazole407.540.0616.7
Outpatient (15,810)Fluconazole21274.51723.52334.8
Voriconazole21310.3175.9220.0
Other NOS (81,517)Fluconazole1,88875.918761.57447.3
Voriconazole1,8627.01863.2748.1
  • a Isolates were obtained from 133 institutions.

  • b % R, percent resistant (zone diameter, ≤14 mm [fluconazole] and ≤13 mm [voriconazole]).